ClinConnect ClinConnect Logo
Search / Trial NCT06485986

Frontosubthalamic Networks in Parkinson's Disease.

Launched by UNIVERSITY OF OXFORD · Jun 26, 2024

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Deep Brain Stimulation

ClinConnect Summary

This clinical trial, titled "Frontosubthalamic Networks in Parkinson's Disease," is aiming to explore why some patients with Parkinson's disease become more impulsive after undergoing deep brain stimulation (DBS) in a specific area of the brain called the subthalamic nucleus. The study will look at how DBS affects brain activity and whether different settings for the stimulation can help reduce impulsivity in these patients.

To participate in this study, individuals must be at least 18 years old and have been diagnosed with Parkinson's disease. They should also have DBS electrodes implanted and may have impulse control disorders or be part of a control group without such disorders. Participants will take part in decision-making tasks while their DBS devices are turned on and off, allowing researchers to monitor their brain activity using a non-invasive brain scan called magnetoencephalography (MEG). It's important to note that participants will need to be able to sit still in the MEG scanner for about three hours and may need to delay their usual medication for a short time. This study is currently recruiting participants, and anyone interested should discuss it with their healthcare provider.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • Diagnosed with Parkinson's disease who have required implanted STN electrodes for DBS in addition to their dopamine replacement therapy.
  • Diagnosed with or without (control group) impulse control disorders since the diagnosis of Parkinson's Disease.
  • Participant willing and able to sit in the MEG scanner and follow instructions.
  • Participant willing and able to delay their morning dose of dopamine replacement therapy for up to four hours (180 minutes experimental time + journey time).
  • Exclusion Criteria:
  • Patients with extreme language barrier that cannot understand the purpose or instructions of the study despite the use of an interpreter.
  • Other implanted medical devices that may cause artefacts during MEG recordings.
  • Participants with a history of co-morbid neurological disorders.
  • Participant enrolled onto another clinical trial related to a neurological disorder (including Parkinson's disease) that may interfere with the results of this study.
  • Participants who are unable to sit still in a MEG scanner for the duration of this experiment e.g. patients with chronic pain or osteoarthritis. This will be assessed with their primary clinician

About University Of Oxford

The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.

Locations

Oxford, , United Kingdom

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported